Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
The HIP ATTACK-2 trial is an international, multicenter randomized controlled study investigating whether accelerated surgery for patients with hip fractures and acute myocardial injury reduces death within 90 days compared to standard care. The trial also evaluates secondary outcomes such as the ability to walk independently, time to first mobilization, major complications including heart and stroke events, delirium, length of hospital stay, pain, and quality of life. Participants are assigned to either accelerated medical clearance with surgery within 6 hours of meeting eligibility or to standard surgical care following hospital guidelines. The accelerated group receives rapid preparation aimed at timely hip fracture repair, while the standard care group undergoes usual surgical timing and procedures. Both groups receive hip fracture repair and surgical care according to treating institution protocols. During the study, participants are monitored for mortality and other health outcomes up to 90 days after randomization. Assessments include walking ability, major cardiovascular events, delirium, pain levels, hospital discharge timing, and overall quality of life. Safety and recovery progress are closely followed to understand the impact of surgery timing on these important measures.
Actively Recruiting
Researchers are evaluating the safety and effects of three different doses of the drug NMD670 compared to a placebo in adults with Myasthenia Gravis who have antibodies against AChR or MuSK. This Phase 2 proof-of-concept study aims to find the appropriate dose by assessing how the drug affects muscle strength over 21 days of treatment. Participants will take either a high, mid, or low dose of NMD670 tablets, or placebo tablets, twice daily for 21 days. The study is randomized and double-blinded, meaning neither participants nor researchers know who receives which dose. The goal is to compare the changes in muscle strength and other symptoms between the different dose groups and placebo during this treatment period. During the study, participants will be monitored for changes in muscle strength using the Quantitative Myasthenia Gravis QMG score and other related clinical assessments. Safety will be closely watched through physical exams, lab tests, vital signs, ECGs, and eye exams from screening through follow-up. The study also tracks any adverse events during the 21-day dosing and follow-up period. Participants will be involved in visits and assessments throughout the trial, which is expected to complete by December 2026.